Search results for: Henry G. Grabowski
Filter search results
New: Priority Review Vouchers and Innovation
17 February 2011
This OHE Seminar Briefing recounts a presentation by Prof Henry Grabowski on US Priority Review Vouchers, intended to provide an incentive for the development of drugs for tropical diseases. One…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US…
OHE Lunchtime Seminar: Interventions that Encourage High-Value Nursing Home Care: Lessons for the UK
18 April 2017, 11:00pm
OHE Lunchtime Seminar with Professor David Grabowski, Harvard University. Countries around the world are struggling with how to provide high-value nursing home care. Many countries are plagued with low-quality care,…
Industrial Policy and the Pharmaceutical Industry
1 January 1995
…the importance of government science and education policy for the discovery and development process. The seventh and eighth papers by Quam and Professor Grabowski respectively explore the role of government…
Consolidation and Competition in the Pharmaceutical Industry
9 January 2001
…motivator for companies to seek larger scale. Grabowski shows that returns from new pharmaceuticals are highly skewed, with only 30 percent of products launched in the early 1980s recovering average…
Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
1 August 2017
This OHE Seminar Briefing summarises a seminar given by Professor David Grabowski, which provided a health economics perspective on how payment and delivery interventions can encourage high-value nursing home care….
Biosimilars: How Much Entry and Price Competition Will Result?
1 December 2010
…impact. Chapter authors include Profs Bengt Jönsson (Stockholm School of Economics), Prof Henry Grabowski (Duke University), Prof Adrian Towse and Dr. Jorge Mestre-Ferrandiz (OHE), Prof Richard G. Frank (Harvard Medical…
Migraine
1 September 1991
‘Choose something common and you will find little is known about it’ (Henry Head to the young Dr Russell Brain c 1920). Although common (8 per cent of the population)…
Estimating US Savings from Biosimilars
13 July 2010
…of biosimilars. It assumes that market share of biosimilars will depend on four factors: FDA judgement about interchangeability, payer treatment, physician prescribing behaviour and consumer demand, and pricing. With respect…